Generating comparative evidence on new drugs and devices before approval
Huseyin Naci(London School of Economics and Political Science), Andrea Cipriani(Oxford Health NHS Foundation Trust), T. Scott Stroup(New York Psychoanalytic Society and Institute), Emily Jackson(Alfred I. duPont Hospital for Children), Lise Rochaix(Assistance Publique – Hôpitaux de Paris), Maximilian Salcher‐Konrad(London School of Economics and Political Science), Beate Wieseler(Institute for Quality and Efficiency in Health Care), Aaron S. Kesselheim(Brigham and Women's Hospital), Georgia Salanti(University of Bern), Rita F. Redberg(University of California, San Francisco), Sarah Garner(National Institute for Health and Care Excellence)
Cited by 80
Related Papers
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
|Annals of Internal Medicine|2015|8.2k
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
|Journal of Clinical Epidemiology|2010|3.8k
Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis
|The Lancet|2018|3.5k
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
|The Lancet|2013|2.5k
Graphical Tools for Network Meta-Analysis in STATA
|PLoS ONE|2013|2.5k